• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/26 6:02:31 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LIVN alert in real time by email
    livn-20260506
    LIVANOVA PLC0001639691false00016396912026-05-062026-05-06

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 6, 2026

    LivaNova Image.jpg

    LivaNova PLC
    (Exact Name of Registrant as Specified in its Charter)
    England and Wales001-3759998-1268150
    (State or Other Jurisdiction
     of Incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

    20 Eastbourne Terrace
    London, W2 6LG
    United Kingdom
    (Address of Principal Executive Offices)

    +44 20 33250660
    (Registrant’s Telephone Number, Including Area Code)

    N/A
    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name on each exchange on which registered
    Ordinary Shares - £1.00 par value per shareLIVNNASDAQ Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    ☐



    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2026, LivaNova PLC (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026. The Company will host a business update conference call and webcast today, May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Time), during which the Company will discuss the financial results. The conference call will be available through the LivaNova website at www.livanova.com/events.

    A copy of the Company’s press release related to the foregoing matters is attached hereto as Exhibit 99.1. The information in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.


    Item 9.01 Financial Statements and Exhibits

    (d)    Exhibits.

    ExhibitDescription
    99.1
    Press Release of LivaNova PLC dated May 6, 2026
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)




    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    LivaNova PLC
    Date: May 6, 2026
    By: /s/ Sarah K. Mohr
    Name: Sarah K. Mohr
    Title: VP, Legal and Company Secretary


    Get the next $LIVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIVN

    DatePrice TargetRatingAnalyst
    12/19/2025$81.00Overweight
    KeyBanc Capital Markets
    10/1/2025$55.00Buy → Neutral
    Goldman
    5/20/2025$60.00Peer Perform → Outperform
    Wolfe Research
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    10/4/2024$65.00Buy
    Goldman
    9/17/2024$55.00 → $66.00Neutral → Outperform
    Robert W. Baird
    3/20/2024Buy
    Needham
    2/20/2024$60.00 → $70.00Neutral → Buy
    Mizuho
    More analyst ratings

    $LIVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LivaNova Appoints Anne Liddy as Chief Legal Officer

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company's global legal and compliance function and serve as a member of the Executive Leadership Team. Liddy brings more than two decades of experience advising global healthcare and life sciences companies on complex legal, regulatory, M&A, and compliance matters. She joins LivaNova from Hologic, Inc., where she most recently served as General Counsel, leading a global legal organization and advising senior leadership and the Board of Directors on critical business, transactional, and compliance initiati

    6/5/26 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership transition before assuming full responsibility for the business on August 1. Folli will join the LivaNova Executive Leadership Team and report to Chief Executive Officer Vladimir Makatsaria. "Stefano is an accomplished healthcare and medtech executive with a sharp blend of strategic vision and operational excellence," Makatsaria said. "With more than t

    5/21/26 9:15:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup of the webcast. A r

    5/19/26 8:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    SEC Filings

    View All

    SEC Form SD filed by LivaNova PLC

    SD - LivaNova PLC (0001639691) (Filer)

    5/29/26 4:13:09 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form IRANNOTICE filed by LivaNova PLC

    IRANNOTICE - LivaNova PLC (0001639691) (Filer)

    5/6/26 1:03:33 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by LivaNova PLC

    10-Q - LivaNova PLC (0001639691) (Filer)

    5/6/26 1:01:33 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bianchi Francesco sold $136,350 worth of Ordinary Shares (1,800 units at $75.75), decreasing direct ownership by 20% to 7,228 units (SEC Form 4)

    4 - LivaNova PLC (0001639691) (Issuer)

    5/27/26 4:51:27 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Tezel Ahmet

    4 - LivaNova PLC (0001639691) (Issuer)

    4/1/26 5:20:30 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Poletti Franco

    4 - LivaNova PLC (0001639691) (Issuer)

    4/1/26 5:20:24 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on LivaNova with a new price target

    KeyBanc Capital Markets initiated coverage of LivaNova with a rating of Overweight and set a new price target of $81.00

    12/19/25 8:50:10 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova downgraded by Goldman with a new price target

    Goldman downgraded LivaNova from Buy to Neutral and set a new price target of $55.00

    10/1/25 8:42:07 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded LivaNova from Peer Perform to Outperform and set a new price target of $60.00

    5/20/25 8:01:26 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LivaNova PLC

    SC 13G - LivaNova PLC (0001639691) (Subject)

    4/17/24 4:19:05 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

    SC 13G/A - LivaNova PLC (0001639691) (Subject)

    2/12/24 4:01:13 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

    SC 13G/A - LivaNova PLC (0001639691) (Subject)

    1/23/24 11:52:27 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Financials

    Live finance-specific insights

    View All

    LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

    – Delivered double-digit reported and constant-currency revenue growth – Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1) – Received U.S. Food and Drug Administration premarket approval for aura6000 System to treat moderate to severe obstructive sleep apnea LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period First-quarter U.S. GAAP diluted

    5/6/26 6:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova to Announce First-Quarter 2026 Results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 946097. A replay will be available on the

    3/25/26 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

    – Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25 – Received increased provider reimbursement from U.S. Centers for Medicare & Medicaid Services for VNS Therapy for Drug-Resistant Epilepsy procedures, effective Jan. 1, 2026, significantly reducing a known barrier to procedure penetration – Received U.S. Food and Drug Administration approval for cloud-based digital health platform LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology com

    2/25/26 6:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Leadership Updates

    Live Leadership Updates

    View All

    LivaNova Appoints Anne Liddy as Chief Legal Officer

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company's global legal and compliance function and serve as a member of the Executive Leadership Team. Liddy brings more than two decades of experience advising global healthcare and life sciences companies on complex legal, regulatory, M&A, and compliance matters. She joins LivaNova from Hologic, Inc., where she most recently served as General Counsel, leading a global legal organization and advising senior leadership and the Board of Directors on critical business, transactional, and compliance initiati

    6/5/26 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary (CP), effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner closely with Poletti over the coming months to ensure a seamless leadership transition before assuming full responsibility for the business on August 1. Folli will join the LivaNova Executive Leadership Team and report to Chief Executive Officer Vladimir Makatsaria. "Stefano is an accomplished healthcare and medtech executive with a sharp blend of strategic vision and operational excellence," Makatsaria said. "With more than t

    5/21/26 9:15:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. "Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector," Makatsaria said. "With her extensive OSA market expertise, she has a strong track record in creating new sleep therapy pathways, improving patient access to care, and building strong commercial teams. Her leadership will help us unlock transformational growth by co

    12/2/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care